Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction
Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since sm...
Gespeichert in:
Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 1995-01, Vol.91 (2), p.298-303 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 303 |
---|---|
container_issue | 2 |
container_start_page | 298 |
container_title | Circulation (New York, N.Y.) |
container_volume | 91 |
creator | GRINES, C. L TOPOL, E. J O'NEILL, W. W GEORGE, B. S KEREIAKES, D PHILLIPS, H. R LEIMBERGER, J. D WOODLIEF, L. H CALIFF, R. M |
description | Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since smoking is associated with a relatively hyper-coagulable state, we hypothesized that the coronary occlusion responsible for infarction may be primarily thrombotic, with improved outcome relating to enhanced patency or the absence of a residual stenosis after thrombolytic therapy.
To examine this issue, we evaluated 1619 patients treated with TPA, urokinase, or both in six consecutive myocardial infarction trials, of whom 878 (54%) were currently smoking. Patients underwent 90-minute and predischarge catheterizations, which were quantified blinded to the patients' smoking status. As expected, baseline fibrinogen (2.8 [2.5,3.6] versus 2.7 [2.4,3.5] g/dL, P = .003) and hematocrit (44% [41%, 47%] versus 43% [40%, 45%], P = .0001) levels were greater in smokers. Although there were no differences between smokers and nonsmokers with regard to 90-minute patency (73% versus 74%), smokers were more likely to have TIMI-3 flow (41.1% versus 34.6%, P = .034), with a larger minimum lumen diameter of the infarct stenosis both acutely (0.82 [0.51, 1.11] versus 0.72 [0.43, 1.04] mm, P = .0432) and at follow-up (1.2 [0.8, 1.74] versus 1.0 [0.7, 1.5], P = .002). Although smokers tended to have reduced in-hospital mortality compared with nonsmokers in univariate analysis (4.0% versus 8.9%, P = .0001), after adjustment for baseline differences between smokers and nonsmokers in age (54 [47, 62] versus 60 [54, 68] years, P < .0001), inferior infarct location (60% versus 53%, P < .0001), three-vessel disease (16% versus 22%, P < .001), and baseline ejection fraction (53% [44%, 60%] versus 50% [42%, 58%], P = .0069), smoking history was of no independent prognostic significance.
Therefore, smokers have a relatively hypercoagulable state, documented by increased hematocrit and fibrinogen levels. Quantitative coronary angiographic analysis suggests that the mechanism of infarction in smokers is more often thrombosis of a less critical atherosclerotic lesion compared with nonsmokers. Enhanced perfusion status, as well as favorable baseline clinical and angiographic characteristics, may be responsible for the more benign prognosis of current smokers. |
doi_str_mv | 10.1161/01.cir.91.2.298 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77090258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23152792</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-e9e3d4d1f70511913aa2d873ac4b432cc09357ab317d2f40d72971f4a294cc523</originalsourceid><addsrcrecordid>eNpdkEFLJDEQhcOyouPsnj0JYZG9dZtK0pPJUQbdFYQF0dMeQk06ceN2d8YkfZh_b8TBg6fiUV-9ejxCzoC1ACu4ZNDakFoNLW-5Xn8hC-i4bGQn9FeyYIzpRgnOT8hpzs9VroTqjsmxWrOOC1iQv9feO1to9NSGJ0yuFEfzGP-H6YnGica52Dg6ir64RMu_FMdtHPYl2Cpcwt2e-pjouI8WUx9woGHymGwJcfpGjjwO2X0_zCV5vLl-2Pxu7v78ut1c3TW2Ri2N0070sgevWAegQSDyfq0EWrmVglvLtOgUbgWonnvJesW1Ai-Ra2mrhViSn---uxRfZpeLGUO2bhhwcnHORimmGe_WFfzxCXyOc5pqNsOBr4SW9fuSXL5DNsWck_Nml8KIaW-AmbfODQOzub03Ggw3tfN6cX6wnbej6z_4Q8l1f3HYY7Y4-ISTDfkDE0Irrbh4BUp0iZk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212639491</pqid></control><display><type>article</type><title>Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>GRINES, C. L ; TOPOL, E. J ; O'NEILL, W. W ; GEORGE, B. S ; KEREIAKES, D ; PHILLIPS, H. R ; LEIMBERGER, J. D ; WOODLIEF, L. H ; CALIFF, R. M</creator><creatorcontrib>GRINES, C. L ; TOPOL, E. J ; O'NEILL, W. W ; GEORGE, B. S ; KEREIAKES, D ; PHILLIPS, H. R ; LEIMBERGER, J. D ; WOODLIEF, L. H ; CALIFF, R. M</creatorcontrib><description>Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since smoking is associated with a relatively hyper-coagulable state, we hypothesized that the coronary occlusion responsible for infarction may be primarily thrombotic, with improved outcome relating to enhanced patency or the absence of a residual stenosis after thrombolytic therapy.
To examine this issue, we evaluated 1619 patients treated with TPA, urokinase, or both in six consecutive myocardial infarction trials, of whom 878 (54%) were currently smoking. Patients underwent 90-minute and predischarge catheterizations, which were quantified blinded to the patients' smoking status. As expected, baseline fibrinogen (2.8 [2.5,3.6] versus 2.7 [2.4,3.5] g/dL, P = .003) and hematocrit (44% [41%, 47%] versus 43% [40%, 45%], P = .0001) levels were greater in smokers. Although there were no differences between smokers and nonsmokers with regard to 90-minute patency (73% versus 74%), smokers were more likely to have TIMI-3 flow (41.1% versus 34.6%, P = .034), with a larger minimum lumen diameter of the infarct stenosis both acutely (0.82 [0.51, 1.11] versus 0.72 [0.43, 1.04] mm, P = .0432) and at follow-up (1.2 [0.8, 1.74] versus 1.0 [0.7, 1.5], P = .002). Although smokers tended to have reduced in-hospital mortality compared with nonsmokers in univariate analysis (4.0% versus 8.9%, P = .0001), after adjustment for baseline differences between smokers and nonsmokers in age (54 [47, 62] versus 60 [54, 68] years, P < .0001), inferior infarct location (60% versus 53%, P < .0001), three-vessel disease (16% versus 22%, P < .001), and baseline ejection fraction (53% [44%, 60%] versus 50% [42%, 58%], P = .0069), smoking history was of no independent prognostic significance.
Therefore, smokers have a relatively hypercoagulable state, documented by increased hematocrit and fibrinogen levels. Quantitative coronary angiographic analysis suggests that the mechanism of infarction in smokers is more often thrombosis of a less critical atherosclerotic lesion compared with nonsmokers. Enhanced perfusion status, as well as favorable baseline clinical and angiographic characteristics, may be responsible for the more benign prognosis of current smokers.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.cir.91.2.298</identifier><identifier>PMID: 7805231</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adolescent ; Adult ; Aged ; Biological and medical sciences ; Cardiology. Vascular system ; Coronary Angiography ; Coronary heart disease ; Heart ; Humans ; Medical sciences ; Middle Aged ; Myocardial Infarction - drug therapy ; Smoking ; Thrombolytic Therapy ; Treatment Outcome ; Vascular Patency ; Ventricular Function, Left</subject><ispartof>Circulation (New York, N.Y.), 1995-01, Vol.91 (2), p.298-303</ispartof><rights>1995 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Jan 15, 1995</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-e9e3d4d1f70511913aa2d873ac4b432cc09357ab317d2f40d72971f4a294cc523</citedby><cites>FETCH-LOGICAL-c524t-e9e3d4d1f70511913aa2d873ac4b432cc09357ab317d2f40d72971f4a294cc523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,3688,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3397972$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7805231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GRINES, C. L</creatorcontrib><creatorcontrib>TOPOL, E. J</creatorcontrib><creatorcontrib>O'NEILL, W. W</creatorcontrib><creatorcontrib>GEORGE, B. S</creatorcontrib><creatorcontrib>KEREIAKES, D</creatorcontrib><creatorcontrib>PHILLIPS, H. R</creatorcontrib><creatorcontrib>LEIMBERGER, J. D</creatorcontrib><creatorcontrib>WOODLIEF, L. H</creatorcontrib><creatorcontrib>CALIFF, R. M</creatorcontrib><title>Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since smoking is associated with a relatively hyper-coagulable state, we hypothesized that the coronary occlusion responsible for infarction may be primarily thrombotic, with improved outcome relating to enhanced patency or the absence of a residual stenosis after thrombolytic therapy.
To examine this issue, we evaluated 1619 patients treated with TPA, urokinase, or both in six consecutive myocardial infarction trials, of whom 878 (54%) were currently smoking. Patients underwent 90-minute and predischarge catheterizations, which were quantified blinded to the patients' smoking status. As expected, baseline fibrinogen (2.8 [2.5,3.6] versus 2.7 [2.4,3.5] g/dL, P = .003) and hematocrit (44% [41%, 47%] versus 43% [40%, 45%], P = .0001) levels were greater in smokers. Although there were no differences between smokers and nonsmokers with regard to 90-minute patency (73% versus 74%), smokers were more likely to have TIMI-3 flow (41.1% versus 34.6%, P = .034), with a larger minimum lumen diameter of the infarct stenosis both acutely (0.82 [0.51, 1.11] versus 0.72 [0.43, 1.04] mm, P = .0432) and at follow-up (1.2 [0.8, 1.74] versus 1.0 [0.7, 1.5], P = .002). Although smokers tended to have reduced in-hospital mortality compared with nonsmokers in univariate analysis (4.0% versus 8.9%, P = .0001), after adjustment for baseline differences between smokers and nonsmokers in age (54 [47, 62] versus 60 [54, 68] years, P < .0001), inferior infarct location (60% versus 53%, P < .0001), three-vessel disease (16% versus 22%, P < .001), and baseline ejection fraction (53% [44%, 60%] versus 50% [42%, 58%], P = .0069), smoking history was of no independent prognostic significance.
Therefore, smokers have a relatively hypercoagulable state, documented by increased hematocrit and fibrinogen levels. Quantitative coronary angiographic analysis suggests that the mechanism of infarction in smokers is more often thrombosis of a less critical atherosclerotic lesion compared with nonsmokers. Enhanced perfusion status, as well as favorable baseline clinical and angiographic characteristics, may be responsible for the more benign prognosis of current smokers.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiology. Vascular system</subject><subject>Coronary Angiography</subject><subject>Coronary heart disease</subject><subject>Heart</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Smoking</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><subject>Vascular Patency</subject><subject>Ventricular Function, Left</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEFLJDEQhcOyouPsnj0JYZG9dZtK0pPJUQbdFYQF0dMeQk06ceN2d8YkfZh_b8TBg6fiUV-9ejxCzoC1ACu4ZNDakFoNLW-5Xn8hC-i4bGQn9FeyYIzpRgnOT8hpzs9VroTqjsmxWrOOC1iQv9feO1to9NSGJ0yuFEfzGP-H6YnGica52Dg6ir64RMu_FMdtHPYl2Cpcwt2e-pjouI8WUx9woGHymGwJcfpGjjwO2X0_zCV5vLl-2Pxu7v78ut1c3TW2Ri2N0070sgevWAegQSDyfq0EWrmVglvLtOgUbgWonnvJesW1Ai-Ra2mrhViSn---uxRfZpeLGUO2bhhwcnHORimmGe_WFfzxCXyOc5pqNsOBr4SW9fuSXL5DNsWck_Nml8KIaW-AmbfODQOzub03Ggw3tfN6cX6wnbej6z_4Q8l1f3HYY7Y4-ISTDfkDE0Irrbh4BUp0iZk</recordid><startdate>19950115</startdate><enddate>19950115</enddate><creator>GRINES, C. L</creator><creator>TOPOL, E. J</creator><creator>O'NEILL, W. W</creator><creator>GEORGE, B. S</creator><creator>KEREIAKES, D</creator><creator>PHILLIPS, H. R</creator><creator>LEIMBERGER, J. D</creator><creator>WOODLIEF, L. H</creator><creator>CALIFF, R. M</creator><general>Lippincott Williams & Wilkins</general><general>American Heart Association, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7X8</scope></search><sort><creationdate>19950115</creationdate><title>Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction</title><author>GRINES, C. L ; TOPOL, E. J ; O'NEILL, W. W ; GEORGE, B. S ; KEREIAKES, D ; PHILLIPS, H. R ; LEIMBERGER, J. D ; WOODLIEF, L. H ; CALIFF, R. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-e9e3d4d1f70511913aa2d873ac4b432cc09357ab317d2f40d72971f4a294cc523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiology. Vascular system</topic><topic>Coronary Angiography</topic><topic>Coronary heart disease</topic><topic>Heart</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Smoking</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><topic>Vascular Patency</topic><topic>Ventricular Function, Left</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GRINES, C. L</creatorcontrib><creatorcontrib>TOPOL, E. J</creatorcontrib><creatorcontrib>O'NEILL, W. W</creatorcontrib><creatorcontrib>GEORGE, B. S</creatorcontrib><creatorcontrib>KEREIAKES, D</creatorcontrib><creatorcontrib>PHILLIPS, H. R</creatorcontrib><creatorcontrib>LEIMBERGER, J. D</creatorcontrib><creatorcontrib>WOODLIEF, L. H</creatorcontrib><creatorcontrib>CALIFF, R. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GRINES, C. L</au><au>TOPOL, E. J</au><au>O'NEILL, W. W</au><au>GEORGE, B. S</au><au>KEREIAKES, D</au><au>PHILLIPS, H. R</au><au>LEIMBERGER, J. D</au><au>WOODLIEF, L. H</au><au>CALIFF, R. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1995-01-15</date><risdate>1995</risdate><volume>91</volume><issue>2</issue><spage>298</spage><epage>303</epage><pages>298-303</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>Smoking is known to be a strong risk factor for premature atherosclerosis, myocardial infarction, and sudden cardiac death. Unexpectedly, in the reperfusion era, investigators have reported that patients who smoke have a more favorable prognosis after thrombolysis compared with non-smokers. Since smoking is associated with a relatively hyper-coagulable state, we hypothesized that the coronary occlusion responsible for infarction may be primarily thrombotic, with improved outcome relating to enhanced patency or the absence of a residual stenosis after thrombolytic therapy.
To examine this issue, we evaluated 1619 patients treated with TPA, urokinase, or both in six consecutive myocardial infarction trials, of whom 878 (54%) were currently smoking. Patients underwent 90-minute and predischarge catheterizations, which were quantified blinded to the patients' smoking status. As expected, baseline fibrinogen (2.8 [2.5,3.6] versus 2.7 [2.4,3.5] g/dL, P = .003) and hematocrit (44% [41%, 47%] versus 43% [40%, 45%], P = .0001) levels were greater in smokers. Although there were no differences between smokers and nonsmokers with regard to 90-minute patency (73% versus 74%), smokers were more likely to have TIMI-3 flow (41.1% versus 34.6%, P = .034), with a larger minimum lumen diameter of the infarct stenosis both acutely (0.82 [0.51, 1.11] versus 0.72 [0.43, 1.04] mm, P = .0432) and at follow-up (1.2 [0.8, 1.74] versus 1.0 [0.7, 1.5], P = .002). Although smokers tended to have reduced in-hospital mortality compared with nonsmokers in univariate analysis (4.0% versus 8.9%, P = .0001), after adjustment for baseline differences between smokers and nonsmokers in age (54 [47, 62] versus 60 [54, 68] years, P < .0001), inferior infarct location (60% versus 53%, P < .0001), three-vessel disease (16% versus 22%, P < .001), and baseline ejection fraction (53% [44%, 60%] versus 50% [42%, 58%], P = .0069), smoking history was of no independent prognostic significance.
Therefore, smokers have a relatively hypercoagulable state, documented by increased hematocrit and fibrinogen levels. Quantitative coronary angiographic analysis suggests that the mechanism of infarction in smokers is more often thrombosis of a less critical atherosclerotic lesion compared with nonsmokers. Enhanced perfusion status, as well as favorable baseline clinical and angiographic characteristics, may be responsible for the more benign prognosis of current smokers.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>7805231</pmid><doi>10.1161/01.cir.91.2.298</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 1995-01, Vol.91 (2), p.298-303 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_77090258 |
source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Adolescent Adult Aged Biological and medical sciences Cardiology. Vascular system Coronary Angiography Coronary heart disease Heart Humans Medical sciences Middle Aged Myocardial Infarction - drug therapy Smoking Thrombolytic Therapy Treatment Outcome Vascular Patency Ventricular Function, Left |
title | Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T22%3A52%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20cigarette%20smoking%20on%20outcome%20after%20thrombolytic%20therapy%20for%20myocardial%20infarction&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=GRINES,%20C.%20L&rft.date=1995-01-15&rft.volume=91&rft.issue=2&rft.spage=298&rft.epage=303&rft.pages=298-303&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.cir.91.2.298&rft_dat=%3Cproquest_cross%3E23152792%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212639491&rft_id=info:pmid/7805231&rfr_iscdi=true |